肺结核是目前世界上最严重的传染病之一,每年造成9百万以上的感染以及1百万的死亡。该病的致病菌-结核杆菌具有很强的药物耐受性,长期的药物治疗很容易使得结核病成为不治之症。因此,发现新的抗结核杆菌免疫应答是治疗结核病的绝佳思路。IL-32是2005年被鉴定出来的一类细胞因子,它对于炎性因子(比如TNF-a,IL-1b)的释放具有重要的促进作用。之前的研究 Tuberculosis is one of the most serious infectious diseases in the world, causing more than 9 million infections and 1 million deaths each year. The pathogenic bacteria - Mycobacterium tuberculosis has a strong drug tolerance, long-term drug treatment can easily make tuberculosis become incurable. Therefore, the discovery of a new anti-tuberculosis immune response is a great way to treat TB. IL-32 is a group of cytokines identified in 2005, which plays an important role in the release of inflammatory cytokines such as TNF-a and IL-1b. Previous research